(12) **Translation of European patent specification**

(11) **NO/EP 3964503 B1**

NORWAY

(19) NO

(51) Int Cl.

C07D 295/205 (2006.01)
A61K 31/496 (2006.01)
A61P 25/00 (2006.01)
A61P 29/00 (2006.01)
C07C 57/15 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2024.02.19
(80)	Date of The European Patent Office Publication of the Granted Patent	2023.11.08
(86)	European Application Nr.	21199077.5
(86)	European Filing Date	2017.11.15
(87)	The European Application's Publication Date	2022.03.09
(30)	Priority	2016.11.16, US, 201662423126 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ; ME
	Designated validation states	MA
(62)	Divided application	EP3541807, 2017.11.15
(73)	Proprietor	H. Lundbeck A/S, Ottiliavej 9, 2500 Valby, Danmark
(72)	Inventor	Grice, Cheryl A., San Diego, 9121, USA Jones, Todd K., San Diego, 92121, USA Grimm, Kurt G., San Diego, 92121, USA Blankman, Jacqueline Lorayne, San Diego, 92121, USA Beals, Channing Rodney, San Diego, 92121, USA
(74)	Agent or Attorney	BRYN AARFLOT AS, Stortingsgata 8, 0161 OSLO, Norge

(54) Title **A CRYSTALLINE FORM OF A MAGL INHIBITOR**

(56) References Cited: US-A1- 2015 018 335

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (http://worldwide.espacenet.com) or via the search engine on our website here: https://search.patentstyret.no/

PATENTKRAV

1. Krystallinsk form av 1,1,1,3,3,3-heksafluorpropan-2-yl-4-(2-(pyrrolidin-1-yl)-4-(trifluormetyl)benzyl)piperazin-1-karboksylatfumaratsalt med et Røntgenpulverdiffraksjonsmønster (XRPD) med karakteristiske topper ved 13,6° 2-Theta, 14,1° 2-Theta, 14,3° 2-Theta, 20,0° 2-Theta og 21,9° 2-Theta.

2. Farmasøytisk sammensetning omfattende den krystallinske formen ifølge krav 1, og minst én inaktiv ingrediens valgt fra farmasøytisk akseptable bærere, fortynningsmidler og hjelpestoffer.

3. Krystallinsk form ifølge krav 1, for anvendelse i behandlingen av multippel sklerose.

4. Krystallinsk form ifølge krav 1, for anvendelse i behandlingen av multippel sklerose ifølge krav 3, hvori behandlingen er for smerte eller spastisitet assosiert med multippel sklerose.